Targeting HER3, either alone or in combination with other EGFR family members could be a promising strategy for HNSCC treatment or may pose a potential pathway to overcome HER and HER2 resistance mechanisms seen in some HNSCC cases. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.